Patients who recieved CT-P13 compared with those who recived Remicade® also achieved similar rates of CDAI-100 response and clinical remission at week 641.
Study results (week 54) indicated similar efficacy in patients switched (at week 30) from Remicade® to CT-P13* compared with those who remained on Remicade®‡ 42.
Efficacy among patients maintained on Remicade® and those switched to CT-P13* at Week 3042
*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA®.
†Remicade® is a registered trademark of MSD.
# Secondary endpoint; not powered to show difference in switch groups.
‡ Statistical data generated from the switch data of Study 3.4 are not powered to demonstrate any comparison and should be treated as descriptive statistics only.
CDAI, Crohn’s Disease Activity Index; CD, Crohn’s disease; CI, Confidence interval; RCT, Randomised controlled trial.
PP-IFA-GBR-0304. December 2018